Compugen is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platforms to identify novel drug targets and new biological pathways and develop therapeutics in the field of cancer immunotherapy. Recognizing the potential of immuno-oncology to shift the cancer treatment landscape, we chose to focus on the discovery of new drug targets to extend the reach of cancer immunotherapies to new patient populations.
This approach, which resulted in three programs in clinical development, is constantly evolving and allows us to discover novel drug targets and develop a deep understanding of cancer biology.
Integrated into our computational discovery capabilities, we have extensive drug target validation processes and drug development capabilities that employ rigorous experimentation. This allows us to identify promising immunotherapy drug candidates and to translate our in-silico findings into first-in-class therapeutics with the potential to improve patient outcomes.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.